Search Results

10 results for cancer

Why We Can’t Wait: A Public Health Approach to Health Disparities in Genomic Medicine

six circles surrounding a circle including this text: Ensuring Effective and Responsible Use of Genomic Medicine to Improve Population Health. Circle 1 text: Community. Circle 2 text: Health Care Delivery System. Circle 3 text: Employers and Business. Circle 4 text: The Media. Circle 5 text: Academia. Circle 6 text: Governmental Public Health Infrastucture

In May 2013, I attended and presented at the “Why We Can’t Wait Conference to Eliminate Health Disparities in Genomic Medicine.”  The conference was organized by the University of Miami and Stanford University, with attendees and speakers from academia, consumer organizations, government agencies, public health, clinical practice, and the private sector. A key rationale for

Posted on by Muin J Khoury, Director, Office of Public Health Genomics, Centers for Disease Control and PreventionTags , , ,

A Public Health Genomic State-by-State Clickable Map: Accelerating Implementation of Genomics Applications to Improve Population Health

US Map

In recent years, public health programs in several states have used innovative approaches to implement evidence-based genomic testing recommendations in an effort to improve health outcomes for people at increased hereditary risk for breast, ovarian, colorectal and other cancers.  For example, the Michigan Department of Community Health [PDF 1.04 MB] has partnered with payers in

Posted on by Karen Greendale, MA, CGC, McKing Consulting, Contractor for the Office of Public Health Genomics, Centers for Disease Control and Prevention1 CommentTags , , , , , , ,

New Products from the EGAPP Working Group: Further Development of Evidence Review Methodology and More Recommendations in Genomic Medicine

EGAPP logo

The independent EGAPP working group (EWG) held its 27th meeting on May 13-14, 2013 via a virtual online venue. The EWG has been very active since the last meeting.  Highlights included: The EWG has four new publications since the last meeting: Recommendations from the EGAPP Working Group: does genomic profiling to assess type 2 diabetes

Posted on by Michael P. Douglas and W. David Dotson, Office of Public Health Genomics, Centers for Disease Control and PreventionTags , ,

Walking Before Running: Genomic Medicine 10 Years After the Human Genome Project

10 year celebration with double helixes

It has been said that the folks at the National Human Genome Research Institute (NHGRI) never pass up the chance for well-deserved celebration – and I should know, I was one of them.  Probably at least a few readers have noticed that the Human Genome Project (HGP) has celebrated a number of milestones and anniversaries over

Posted on by W. Gregory Feero, MD, PhD, Maine Dartmouth Family Medicine Residency1 Comment

On Spinning Wheels and Genomes Revealed:

sleeping beauty

Sequencing is No Longer a Sleeping Controversy In the classic Disney version of the fairy tale, Sleeping Beauty is hidden in the woods to protect her from the knowledge of an evil curse… but when she later pricks her finger on a spinning wheel, she falls under a fairy’s spell… Unlike the mythical magic of

Posted on by Scott Bowen and Muin J Khoury, Office of Public Health Genomics, Centers for Disease Control and Prevention

Implementing Evidence-based Genomics Recommendations at the Intersection of Public Health and Healthcare

several publications from Michigan

We take the opportunity of March 22, 2013, designated as Lynch Syndrome Awareness Day by 13 U.S. state governors and counting, to highlight state public health genomics programs that are taking innovative approaches to implement evidence-based genomic testing recommendations for hereditary cancer syndromes, including Lynch syndrome. 

Posted on by Jenna McLosky and Debra Duquette, Michigan Department of Community Health Beverly Burke and Joan Foland, Connecticut Department of Public HealthTags , ,

Accelerating the Development of Evidence Reviews and Recommendations in Genomic Medicine

EGAPP logo

The independent EGAPP working group (EWG) held its 26th meeting on February 11-12, 2013 at the CDC campus in Atlanta. Highlights included: Three EWG recommendation statements on the validity and utility of genetic tests are pending publication on: KRAS, BRAF and other markers involved in EGFR signaling, which are used to inform choice of therapies for

Posted on by Michael P. Douglas and W. David Dotson, Office of Public Health Genomics, Centers for Disease Control and PreventionTags , , ,

How Can We Use Genetic Testing in Population Screening for Common Diseases?

People on the street

Scientific and implementation challenges Population screening for disease  is a concept that has been around for many decades. Its main purpose is early detection and treatment of asymptomatic disease, or risk assessment and prevention of future disease, in order to improve health outcomes in individuals and populations. Examples include mammography in breast cancer screening and

Posted on by Muin J Khoury, Director, Office of Public Health Genomics, Centers for Disease Control and Prevention1 CommentTags , ,

Public Health Genomics: 15 Years On

double helix with the number 15

In 2012, the United States and the United Kingdom marked 15 years of public health genomics, a multidisciplinary field that deals with the effective and responsible translation of genome-based science to improve population health. Fifteen years ago, a new era of personalized healthcare and disease prevention seemed only around the corner. However, the promise of

Posted on by Muin J Khoury, Director, Office of Public Health Genomics, Centers for Disease Control and PreventionTags , ,

From Genetic Counseling in Individuals to Cascade Screening in Populations: An Emerging Role for Public Health Practice

genetic counseling

There are more than 2500 diseases for which genetic testing is currently available. Most of these diseases are individually rare conditions but collectively affect millions of individuals and families worldwide. Genetic diseases are usually caused by mutations in one or a few genes that may confer a high risk of illness, disability and early death.

Posted on by Muin J Khoury, Director, Office of Public Health Genomics, Centers for Disease Control and Prevention1 CommentTags ,